Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy

References

• Zaccardi F, Webb DR, Yates T, et al. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2016 Feb;92(1084):63–69.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim JH, Kim KW, et al. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology. 2009 Dec 16;20(50):505101.
   PubMed Web of Science ®Google Scholar
• Cao Y, Samy KE, Bernards DA, et al., Recent advances in intraocular sustained-release drug delivery devices. Drug Discov Today. 24(8): 1694–1700. 2019.
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463.
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in anchor, marina, and horizon: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299.
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146. e3.
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant. Arch Ophthalmol. 2008;126(9):1191–1201.
   PubMedGoogle Scholar
• Fangueiro JF, Silva AM, Garcia ML, et al. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm. 2015;95:307–322.
   PubMed Web of Science ®Google Scholar
• Fangueiro J, Gonzalez-Mira E, Martins-Lopes P, et al. A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing. Pharm Dev Technol. 2013;18(3):545–549.
   PubMed Web of Science ®Google Scholar
• Fangueiro JF, Silva AM, Garcia ML, et al. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm. 2015 Sep;95(Pt B):307–322.
   PubMedGoogle Scholar
• Amadio M, Bucolo C, Leggio G, et al. The PKCβ/HuR/VEGF pathway in diabetic retinopathy. Biochem Pharmacol. 2010;80(8):1230–1237.
   PubMed Web of Science ®Google Scholar
• Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017;139:7–14.
   PubMed Web of Science ®Google Scholar
• Platania CBM, Leggio GM, Drago F, et al. Computational systems biology approach to identify novel pharmacological targets for diabetic retinopathy. Biochem Pharmacol. 2018;158:13–26.
   PubMed Web of Science ®Google Scholar
• Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr Eye Res. 2011 Dec;36(12):1069–1077.
   PubMed Web of Science ®Google Scholar
• Miwa K, Nakamura J, Hamada Y, et al. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract. 2003 Apr;60(1):1–9.
   PubMed Web of Science ®Google Scholar
• Naruse K, Nakamura J, Hamada Y, et al. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res. 2000 Sep;71(3):309–315.
   PubMed Web of Science ®Google Scholar
• Platania CBM, Lazzara F, Fidilio A, et al. Blood-retinal barrier protection against high glucose damage: the role of P2X7 receptor. Biochem Pharmacol. 2019 Oct;168:249–258.
   PubMed Web of Science ®Google Scholar
• Platania CBM, Giurdanella G, Di Paola L, et al. P2X7 receptor antagonism: implications in diabetic retinopathy. Biochem Pharmacol. 2017 Aug 15;138:130–139.
   PubMed Web of Science ®Google Scholar
• Tsai T, Kuehn S, Tsiampalis N, et al. Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. PLoS One. 2018;13(3):1–13.
   Web of Science ®Google Scholar
• Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998 Jun;47(6):859–866.
   PubMed Web of Science ®Google Scholar
• Amadio M, Pascale A, Cupri S, et al. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacol Res. 2016 Sep;111:713–720.
   PubMed Web of Science ®Google Scholar
• Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol. 2003 Oct;201(2):328–333.
   PubMed Web of Science ®Google Scholar
• Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care. 1999 Mar;22(Suppl 2):B65–71.
   PubMedGoogle Scholar
• Nakamura M, Barber AJ, Antonetti DA, et al. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J Biol Chem. 2001 Nov 23;276(47):43748–43755.
   PubMed Web of Science ®Google Scholar
• Franken AA, Derkx FH, Schalekamp MA, et al. Association of high plasma prorenin with diabetic retinopathy. J Hypertens Suppl. 1988 Dec;6(4):S461–463.
   PubMedGoogle Scholar
• Luetscher JA, Kraemer FB, Wilson DM, et al. Increased plasma inactive renin in diabetes mellitus. N Engl J Med. 1985;312(22):1412–1417.
   PubMed Web of Science ®Google Scholar
• Elakkiya M, Selvaraj K, Current KG. Emerging therapies for the management of diabetic retinopathy. J Appl Pharm Sci. 2017;7(9):243–251.
   Google Scholar
• Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):283–290.
   PubMed Web of Science ®Google Scholar
• Seki M, Tanaka T, Nawa H, et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes. 2004 Sep;53(9):2412–2419.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tao L, Fu X, et al. BDNF protects retinal neurons from hyperglycemia through the TrkB/ERK/MAPK pathway. Mol Med Rep. 2013 Jun;7(6):1773–1778.
   PubMed Web of Science ®Google Scholar
• Ola MS, Nawaz MI, El-Asrar AA, et al. Reduced levels of brain derived neurotrophic factor (BDNF) in the serum of diabetic retinopathy patients and in the retina of diabetic rats. Cell Mol Neurobiol. 2013 Apr;33(3):359–367.
   PubMed Web of Science ®Google Scholar
• Chitranshi N, Gupta V, Kumar S, et al. Exploring the molecular interactions of 7,8-Dihydroxyflavone and its derivatives with TrkB and VEGFR2 proteins. Int J Mol Sci. 2015 Sep;16(9):21087–21108.
   PubMed Web of Science ®Google Scholar
• Chitranshi N, Dheer Y, Gupta V, et al. PTPN11 induces endoplasmic stress and apoptosis in SH-SY5Y cells. Neuroscience. 2017 Nov 19;364:175–189.
   PubMed Web of Science ®Google Scholar
• Chitranshi N, Dheer Y, Mirzaei M, et al. Loss of Shp2 rescues BDNF/TrkB signaling and contributes to improved retinal ganglion cell neuroprotection. Mol Ther. 2019 Feb 6;27(2):424–441.
   PubMed Web of Science ®Google Scholar
• Lu L, Jiang Y, Jaganathan R, et al. Current advances in pharmacotherapy and technology for diabetic retinopathy: A systematic review. J Ophthalmol. 2018;2018:1694187..
   PubMed Web of Science ®Google Scholar
• Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20(3):244–250.
   PubMed Web of Science ®Google Scholar
• Sheshala R, Hong GC, Yee WP, et al. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide. Drug Deliv Transl Res. 2019;9(2):534–542.
   PubMed Web of Science ®Google Scholar
• McAvoy K, Jones D, Thakur RRS. Synthesis and characterisation of photocrosslinked poly (ethylene glycol) diacrylate implants for sustained ocular drug delivery. Pharm Res. 2018;35(2):1–17.
   Web of Science ®Google Scholar
• Haller JA. Intraocular steroids in the office. New formulations offer preservative-free triamcinolone without relying on compounding pharmacies. Retin Phys. 2009;1:45–47.
   Google Scholar
• PIERAMICI DJ. I-vation implant technology. Retin Physician. 2007;4(7):24–25.
   Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):626–635 e2.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four–week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–1027.
   PubMed Web of Science ®Google Scholar
• Pacella F, Ferraresi AF, Turchetti P, et al. Intravitreal injection of Ozurdex® implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis. 2016;8:11–16.
   PubMedGoogle Scholar
• Lee SS, Yuan SSP, Robinson SSPMR Ocular implants for drug delivery. Encyclopedia of biomaterials and biomedical engineering: CRC Press; 2008. p. 1981–1995.
   Google Scholar
• Bode C, Kranz H, Siepmann F, et al. In-situ forming PLGA implants for intraocular dexamethasone delivery. Int J Pharm. 2018;548(1):337–348.
   PubMedGoogle Scholar
• Bucolo C, Gozzo L, Longo L, et al., Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. J Pharmacol Sci. 138(4): 219–232. 2018.
   PubMed Web of Science ®Google Scholar
• Gupta M, Majumdar D. Effect of concentration, pH, and preservative on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian J Exp Bio. 1997;35(8):844–849.
   PubMedGoogle Scholar
• Ahuja M, Dhake AS, Majumdar DK. Effect of formulation factors on in vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat cornea. Yakugaku Zasshi. 2006;126(12):1369–1375.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10836–10841.
   PubMed Web of Science ®Google Scholar
• Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007 Feb;56(2):373–379.
   PubMed Web of Science ®Google Scholar
• Zheng L, Howell SJ, Hatala DA, et al. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007 Feb;56(2):337–345.
   PubMed Web of Science ®Google Scholar
• Valiatti FB, Crispim D, Benfica C, et al. [The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy]. Arq Bras Endocrinol Metabol. 2011 Mar;55(2):106–113.
   PubMedGoogle Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• Schmidinger G, Maar N, Bolz M, et al. Repeated intravitreal bevacizumab (Avastin((R))) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011 Feb;89(1):76–81.
   PubMed Web of Science ®Google Scholar
• Vaishya R, Khurana V, Patel S, et al. Long-term delivery of protein therapeutics. Expert Opin Drug Deliv. 2015;12(3):415–440.
   PubMed Web of Science ®Google Scholar
• Badiee P, Varshochian R, Rafiee‐Tehrani M, et al. Ocular implant containing bevacizumab‐loaded chitosan nanoparticles intended for choroidal neovascularization treatment. J Biomed Mater Res A. 2018;106(8):2261–2271.
   PubMed Web of Science ®Google Scholar
• Matsumiya W, Honda S, Bessho H, et al. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol. 2011;2011:742020.
   PubMed Web of Science ®Google Scholar
• Moradi A, Sepah YJ, Sadiq MA, et al. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes. 2013 Dec 15;4(6):303–309.
   PubMedGoogle Scholar
• Khanna S, Komati R, Eichenbaum DA, et al. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):1–8.
   Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84.
   PubMed Web of Science ®Google Scholar
• Khurana R. Safety and efficacy of abicipar in patients with neovascular age-related macular degeneration. Lect Present Am Acad Ophthalmol. 2018;9(3):250–259.
   Google Scholar
• Kuppermann BD, Thomas EL, de Smet MD, et al. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585–597.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez F, Rodriguez-Blanco M, Gomez-Ulla F, et al. Enzymatic vitreolysis. Curr Diabetes Rev. 2009 Feb;5(1):57–62.
   PubMedGoogle Scholar
• Varma R, Haller JA, Kaiser PK. Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion: results of the microplasmin for intravitreous injection-traction release without surgical treatment (MIVI-TRUST) trials. JAMA Ophthalmol. 2015 Sep;133(9):997–1004.
   PubMed Web of Science ®Google Scholar
• Chen XR, Besson VC, Palmier B, et al. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma. 2007 Jul;24(7):1119–1131.
   PubMed Web of Science ®Google Scholar
• Scott R, Best J, Forder P, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol. 2005;4:13.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697.
   PubMed Web of Science ®Google Scholar
• Group AS, Group AES. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009;15(5):479–489.
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Hata Y, Miura M, Asato R, et al. Antiangiogenic mechanisms of simvastatin in retinal endothelial cells. Graefe’s Arch Clin Exp Ophthalmol. 2010;248(5):667–673.
   PubMed Web of Science ®Google Scholar
• Dorecka M, Francuz T, Garczorz W, et al. The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1,-2,-9 and tissue inhibitor of metalloproteinases-1,-2,-3 expression in human retinal pigment epithelial cells. Acta Biochim Pol. 2014;61(2):265–270.
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Hein TW, Yoshida A, et al. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways. Invest Ophthalmol Vis Sci. 2007;48(2):825–832.
   PubMed Web of Science ®Google Scholar
• Fernandes R, Bento CF, Matafome P, et al. Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia. Can J Physiol Pharmacol. 2014;92(12):1037–1043.
   PubMed Web of Science ®Google Scholar
• Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49(7):3231–3238.
   PubMed Web of Science ®Google Scholar
• Li J, Wang JJ, Yu Q, et al. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010;59(6):1528–1538.
   PubMed Web of Science ®Google Scholar
• Li J, Wang JJ, Chen D, et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood–retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res. 2009;89(1):71–78.
   PubMed Web of Science ®Google Scholar
• Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol. 2004;164(5):1697–1706.
   PubMed Web of Science ®Google Scholar
• Dal Monte M, Ristori C, Cammalleri M, et al. Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3596–3606.
   PubMed Web of Science ®Google Scholar
• Panagiotoglou TD, Ganotakis ES, Kymionis GD, et al. Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol. Ophthalmic Surg Lasers Imaging Retina. 2010;41(3):316–322.
   Web of Science ®Google Scholar
• Gupta A, Gupta V, Thapar S, et al. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol. 2004;137(4):675–682.
   PubMed Web of Science ®Google Scholar
• Vaajanen A, Lakkisto P, Virtanen I, et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol. 2010 Jun;88(4):431–438.
   PubMed Web of Science ®Google Scholar
• Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 Jul 2;361(1):40–51.
   PubMed Web of Science ®Google Scholar
• Willis LM, El-Remessy AB, Somanath PR, et al. Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond). 2011 Apr;120(8):307–319.
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008 Oct 18;372(9647):1394–1402.
   PubMed Web of Science ®Google Scholar
• Baudoin C, Passa P, Sharp P, et al. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic-retinopathy - a multicenter randomized controlled clinical-trial. Diabetes. 1989 Apr;38(4):491–498.
   PubMed Web of Science ®Google Scholar
• Satofuka S, Ichihara A, Nagai N, et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes. 2009 Jul;58(7):1625–1633.
   PubMed Web of Science ®Google Scholar
• Selvaraj K, Gowthamarajan K, Karri VV, et al. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. J Drug Target. 2017 Jun;25(5):386–405.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 2009 Apr;127(4):494–499.
   PubMedGoogle Scholar
• Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase C beta inhibition using ruboxistaurin efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase C beta inhibitor-diabetic retinopathy study and the protein kinase C beta inhibitor-diabetic retinopathy study 2. Retina-J Ret Vit Dis. 2011 Nov;31(10):2084–2094.
   PubMed Web of Science ®Google Scholar
• Poulsen JE. Recovery from retinopathy in a case of diabetes with Simmonds’ disease. Diabetes. 1953 Jan-Feb;2(1):7–12.
   PubMed Web of Science ®Google Scholar
• Dal Monte M, Ristori C, Cammalleri M, et al. Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci. 2009;50(8):3596–3606.
   PubMed Web of Science ®Google Scholar
• Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23(4):504–509.
   PubMed Web of Science ®Google Scholar
• Henry RP. Multiple roles of carbonic anhydrase in cellular transport and metabolism. Annu Rev Physiol. 1996;58(1):523–538.
   PubMedGoogle Scholar
• Wang C-Z, Basila D, Aung HH, et al. Effects of Ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. Am J Chin Med. 2005;33(5):807–815.
   PubMed Web of Science ®Google Scholar
• Agrawal SS, Naqvi S, Gupta SK, et al. Prevention and management of diabetic retinopathy in STZ diabetic rats by Tinospora cordifolia and its molecular mechanisms. Food Chem Toxicol. 2012;50(9):3126–3132.
   PubMed Web of Science ®Google Scholar
• Halim EM, Mukhopadhyay A. Effect ofOcimum sanctum (Tulsi) and vitamin E on biochemical parameters and retinopathy in streptozotocin induced diabetic rats. Indian J Clin Biochem. 2006;21(2):181–188.
   PubMedGoogle Scholar
• Aldebasi YH, Aly SM, Rahmani AH. Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways. Int J Physiol Pathophysiol Pharmacol. 2013;5(4):194–202.
   PubMedGoogle Scholar
• Gupta SK, Kumar B, Nag TC, et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther. 2011;27(2):123–130.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Drago F, Maisto R, et al., Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2‐mediated activation of the Nrf2/HO‐1 pathway. J Cell Physiol. 234(10): 17295–17304. 2019.
   PubMed Web of Science ®Google Scholar
• Alshamrani M, Sikder S, Coulibaly F, et al. Self-assembling topical nanomicellar formulation to improve curcumin absorption across ocular tissues. AAPS PharmSciTech. 2019;20(7):1–16.
   Web of Science ®Google Scholar
• Steigerwalt R, Belcaro G, Cesarone MR, et al. Pycnogenol® improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther. 2009;25(6):537–540.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Cooney MJ, Tu AH, et al. Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest Ophthalmol Vis Sci. 2001;42(9):2110–2114.
   PubMed Web of Science ®Google Scholar
• Kumar B, Gupta SK, Nag TC, et al. Green tea prevents hyperglycemia-induced retinal oxidative stress and inflammation in streptozotocin-induced diabetic rats. Ophthalmic Res. 2012;47(2):103–108.
   PubMed Web of Science ®Google Scholar
• Parveen A, Kim JH, Oh BG, et al. Phytochemicals: target-based therapeutic strategies for diabetic retinopathy. Molecules. 2018;23(7):1–30.
   Web of Science ®Google Scholar
• Neal SE, Buehne KL, Besley NA, et al. Resveratrol protects against hydroquinone-induced oxidative threat in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2020;61(4):1–12.
   Web of Science ®Google Scholar
• Gonzalez VH, Giuliari GP, Banda RM, et al. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol. 2009 Nov;93(11):1474–1478.
   PubMed Web of Science ®Google Scholar
• Group DS. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes. 1989;38(4):491–498.
   PubMed Web of Science ®Google Scholar
• Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol. 2005;4(4):199–203.
   PubMedGoogle Scholar
• Henry RP. Multiple roles of carbonic anhydrase in cellular transport and metabolism. Annu Rev Physiol. 1996;58:523–538.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cordero A, West EL, Pearson RA, et al. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat Biotechnol. 2013;31(8):741–747.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012;3:1–3.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):1–9.
   PubMedGoogle Scholar
• Kompella UB, Amrite AC, Ravi RP, et al. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013 Sep;36:172–198.
   PubMed Web of Science ®Google Scholar
• Elsaid N, Somavarapu S, Jackson TL. Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus. Exp Eye Res. 2014 Apr;121:121–129.
   PubMed Web of Science ®Google Scholar
• Rajala A, Wang YH, Zhu Y, et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 2014 Sep;14(9):5257–5263.
   PubMed Web of Science ®Google Scholar
• Bogdanov P, Sampedro J, Solà-Adell C, et al. Effects of liposomal formulation of citicoline in experimental diabetes-induced retinal neurodegeneration. Int J Mol Sci. 2018;19(8):1–15.
   Web of Science ®Google Scholar
• Tan G, Yu S, Pan H, et al. Bioadhesive chitosan-loaded liposomes: a more efficient and higher permeable ocular delivery platform for timolol maleate. Int J Biol Macromol. 2017;94:355–363.
   PubMed Web of Science ®Google Scholar
• Joseph RR, Tan DWN, Ramon MRM, et al. Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab. Sci Rep. 2017;7(1):1–10.
   PubMedGoogle Scholar
• Kawakami S, Harada A, Sakanaka K, et al. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int J Pharm. 2004;278(2):255–262.
   PubMedGoogle Scholar
• Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci. 2002;43(1):253–259.
   PubMed Web of Science ®Google Scholar
• Campos EJ, Campos A, Martins J, et al. Opening eyes to nanomedicine: where we are, challenges and expectations on nanotherapy for diabetic retinopathy. Nanomedicine. 2017;13(6):2101–2113.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu CH, Ji T, et al. Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles. Nat Commun. 2019 Feb 18;10(1):1–9.
   PubMed Web of Science ®Google Scholar
• Amato R, Dal Monte M, Lulli M, et al. Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Curr Neuropharmacol. 2018;16(7):993–1003.
   PubMed Web of Science ®Google Scholar
• Nor NM, Guo CX, Rupenthal ID, et al. Sustained connexin43 mimetic peptide release from loaded nanoparticles reduces retinal and choroidal photodamage. Invest Opthalmol Visual Sci. 2018;59(8):3682–3693.
   PubMed Web of Science ®Google Scholar
• Amadio M, Pascale A, Cupri S, et al. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacol Res. 2016;111:713–720.
   PubMed Web of Science ®Google Scholar
• Jaiswal M, Dudhe R, Sharma P. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123–127.
   PubMedGoogle Scholar
• Patel N, Nakrani H, Raval M, et al. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Drug Deliv. 2016;23(9):3712–3723.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Patel A, Dutt Vadlapudi A, et al. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed. 2012;2(2):82–95.
   PubMedGoogle Scholar
• Chopra P, Hao J, Li SK. Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera. J Control Release. 2012;160(1):96–104.
   PubMed Web of Science ®Google Scholar
• Vaishya RD, Gokulgandhi M, Patel S, et al. Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. Aaps Pharmscitech. 2014;15(5):1238–1251.
   PubMed Web of Science ®Google Scholar
• Mandal A, Gote V, Pal D, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa®) for dry eye disease. Pharm Res. 2019;36(2):36.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014 Nov 10;193:100–112.
   PubMed Web of Science ®Google Scholar
• Amato R, Dal Monte M, Lulli M, et al. Nanoparticle-mediated delivery of neuroprotective substances for the treatment of diabetic retinopathy. Curr Neuropharmacol. 2018;16(7):993–1003.
   PubMed Web of Science ®Google Scholar
• Tatke A, Dudhipala N, Janga KY, et al. In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials (Basel). 2019 27;9(1):1–17.
   Google Scholar
• Ahangarpour A, Oroojan AA, Khorsandi L, et al. Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse. Oxid Med Cell Longev. 2018;2018:7496936.
   PubMed Web of Science ®Google Scholar
• Shazly GA. Ciprofloxacin controlled-solid lipid nanoparticles: characterization, in vitro release, and antibacterial activity assessment. Biomed Res Int. 2017;2017. DOI:10.1155/2017/2120734.
   Web of Science ®Google Scholar
• Del Pozo-Rodriguez A, Delgado D, Solinis M, et al. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm. 2008;360(1–2):177–183.
   PubMedGoogle Scholar
• Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials. 2012;33(3):979–988.
   PubMed Web of Science ®Google Scholar
• Kambhampati SP, Clunies-Ross AJ, Bhutto I, et al. Systemic and intravitreal delivery of dendrimers to activated microglia/macrophage in ischemia/reperfusion mouse retina. Invest Ophthalmol Vis Sci. 2015;56(8):4413–4424.
   PubMed Web of Science ®Google Scholar
• Yavuz B, Pehlivan SB, Vural İ, et al. In vitro/in vivo evaluation of dexamethasone—PAMAM dendrimer complexes for retinal drug delivery. J Pharm Sci. 2015;104(11):3814–3823.
   PubMed Web of Science ®Google Scholar
• Wimmer N, Marano RJ, Kearns PS, et al. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg Med Chem Lett. 2002;12(18):2635–2637.
   PubMed Web of Science ®Google Scholar
• Bejjani RA, BenEzra D, Cohen H, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis. 2005;11(2):124–132.
   PubMedGoogle Scholar
• Bourges J-L, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562–3569.
   PubMed Web of Science ®Google Scholar
• Selvaraj K, Kuppusamy G, Krishnamurthy J, et al., Repositioning of itraconazole for the management of ocular neovascularization through surface-modified nanostructured lipid carriers. Assay Drug Dev Technol. 17(4): 178–190. 2019.
   PubMed Web of Science ®Google Scholar
• Paterniti I, Di Paola R, Campolo M, et al. Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2015;769:313–323.
   PubMed Web of Science ®Google Scholar
• Platania CBM, Dei Cas M, Cianciolo S, et al. Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. Drug Deliv. 2019;26(1):237–243.
   PubMed Web of Science ®Google Scholar
• Lowe T, Misra G, Daley D, et al. Tailored nanogels for controlled delivery of therepeutics across ocular biological barriers. Invest Ophthalmol Vis Sci. 2009;50(13):2425.
   Google Scholar
• Zhang J, Misra GP, Chang SP, et al. Charged nanogels efficiently overcome ocular biological barriers. Invest Ophthalmol Vis Sci. 2011;52(14):429.
   Google Scholar
• Nasr FH, Khoee S. Design, characterization and in vitro evaluation of novel shell crosslinked poly (butylene adipate)-co-N-succinyl chitosan nanogels containing loteprednol etabonate: a new system for therapeutic effect enhancement via controlled drug delivery. Eur J Med Chem. 2015;102:132–142.
   PubMed Web of Science ®Google Scholar
• Jamard M, Hoare T, Sheardown H. Nanogels of methylcellulose hydrophobized with N-tert-butylacrylamide for ocular drug delivery. Drug Deliv Transl Res. 2016;6(6):648–659.
   PubMed Web of Science ®Google Scholar
• Saenger W, Jacob J, Gessler K, et al. Structures of the common cyclodextrins and their larger analogues beyond the doughnut. Chem Rev. 1998;98(5):1787–1802.
   PubMed Web of Science ®Google Scholar
• Hapiot F, Tilloy S, Monflier E. Cyclodextrins as supramolecular hosts for organometallic complexes. Chem Rev. 2006;106(3):767–781.
   PubMed Web of Science ®Google Scholar
• Soliman O-AE-A, Mohamed EAM, El-Dahan MS, et al. Potential use of cyclodextrin complexes for enhanced stability, anti-inflammatory efficacy, and ocular bioavailability of loteprednol etabonate. AAPS PharmSciTech. 2017;18(4):1228–1241.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Hreinsdóttir D, Stefansson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol. 2007;59(5):629–635.
   PubMed Web of Science ®Google Scholar
• Kam JH, Lynch A, Begum R, et al. Topical cyclodextrin reduces amyloid beta and inflammation improving retinal function in ageing mice. Exp Eye Res. 2015;135:59–66.
   PubMed Web of Science ®Google Scholar
• Algar WR, Tavares AJ, Krull UJ. Beyond labels: a review of the application of quantum dots as integrated components of assays, bioprobes, and biosensors utilizing optical transduction. Anal Chim Acta. 2010;673(1):1–25.
   PubMed Web of Science ®Google Scholar
• Pathak S, Cao E, Davidson MC, et al. Quantum dot applications to neuroscience: new tools for probing neurons and glia. J Neurosci. 2006;26(7):1893–1895.
   PubMed Web of Science ®Google Scholar
• Pollinger K, Hennig R, Ohlmann A, et al. Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application. Proc Nat Acad Sci. 2013;110(15):6115–6120.
   PubMed Web of Science ®Google Scholar
• Olson JL, Velez-Montoya R, Mandava N, et al. Intravitreal silicon-based quantum dots as neuroprotective factors in a model of retinal photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2012;53(9):5713–5721.
   PubMed Web of Science ®Google Scholar
• Savla R, Taratula O, Garbuzenko O, et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 2011;153(1):16–22.
   PubMed Web of Science ®Google Scholar
• Amato R, Giannaccini M, Dal Monte M, et al. Association of the somatostatin analog octreotide with magnetic nanoparticles for intraocular delivery: a possible approach for the treatment of diabetic retinopathy. Front Bioeng Biotechnol. 2020;8:144.
   PubMed Web of Science ®Google Scholar
• Rong X, Ji Y, Zhu X, et al. Neuroprotective effect of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats. Int J Nanomedicine. 2019;14:45–55.
   PubMed Web of Science ®Google Scholar
• Zeng L, Ma W, Shi L, et al. Poly (lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy. Int J Nanomedicine. 2019;14:6357–6369.
   PubMed Web of Science ®Google Scholar
• Qiu F, Meng T, Chen Q, et al. Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration. Mol Pharm. 2019;16(5):1958–1970.
   PubMedGoogle Scholar
• Shoval A, Markus A, Zhou Z, et al. Anti‐VEGF‐aptamer modified C‐dots—A hybrid nanocomposite for topical treatment of ocular vascular disorders. Small. 2019;15(40):1–10.
   Web of Science ®Google Scholar
• Mahaling B, Srinivasarao DA, Raghu G, et al. A non-invasive nanoparticle mediated delivery of triamcinolone acetonide ameliorates diabetic retinopathy in rats. Nanoscale. 2018;10(35):16485–16498.
   PubMed Web of Science ®Google Scholar
• Gote V, Sikder S, Sicotte J, et al. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370(3):602–624.
   PubMed Web of Science ®Google Scholar
• Thakur Singh RR, Tekko I, McAvoy K, et al. Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv. 2017;14(4):525–537.
   PubMed Web of Science ®Google Scholar
• Bian F, Shin CS, Wang C, et al. Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye. Invest Ophthalmol Vis Sci. 2016;57(7):3222–3230.
   PubMed Web of Science ®Google Scholar
• Yuan X, Marcano DC, Shin CS, et al. Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS Nano. 2015;9(2):1749–1758.
   PubMed Web of Science ®Google Scholar
• Stahel M, Becker M, Graf N, et al. Systemic interleukin 1β inhibition in proliferative diabetic retinopathy: a prospective open-label study using canakinumab. Retina (Philadelphia, Pa). 2016;36(2):385–391.
   PubMed Web of Science ®Google Scholar
• Scott IU, Jackson GR, Quillen DA, et al. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non–high-risk proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2014;132(5):535–543.
   PubMed Web of Science ®Google Scholar
• Pakzad-Vaezi K, Albiani DA, Kirker AW, et al. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imag Retina. 2014;45(6):521–524.
   PubMed Web of Science ®Google Scholar
• Virgili G, Menchini F, Casazza G, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:1–18.
   Google Scholar
• Carrasco E, Hernández C, Miralles A, et al. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 2007;30(11):2902–2908.
   PubMed Web of Science ®Google Scholar
• Leske MC, Wu S-Y, Hennis A, et al. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados eye studies. Ophthalmology. 2005;112(5):799–805.
   PubMed Web of Science ®Google Scholar